Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.46 |
| ▸ | PPARG | P37231 | 7/20 | 0.46 |
| ▸ | PPARD | Q03181 | 7/20 | 0.46 |
| ▸ | PPARA | Q07869 | 7/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31239023 | 0.78 | DNM1 (0.42) | TSHRGPR84PPARGPPARDPPARA | |
| SCHEMBL1200063 | 0.78 | TSHR (0.55) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL10499255 | 0.78 | TSHR (0.55) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL6518459 | 0.75 | TSHR (0.50) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL11709128 | 0.75 | TSHR (0.50) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL11252438 | 0.74 | EPHX2 (0.50) | TSHRLMNANFKB1PMP22GPR84 | |
| Octanedioate SCHEMBL1539264 | 0.74 | TSHR (0.80) | TSHRLMNANFKB1PMP22GPR84 | |
| Azelaic Acid SCHEMBL1539243 | 0.74 | TSHR (0.80) | TSHRLMNANFKB1PMP22GPR84 | |
| Sebacic Acid SCHEMBL15111284 | 0.74 | TSHR (0.80) | TSHRLMNANFKB1PMP22GPR84 | |
| Pimelic Acid SCHEMBL28802731 | 0.74 | TSHR (0.80) | TSHRLMNANFKB1PMP22GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3148577-B1 | NOVEL SEMI-SYNTHETIC MENINGOCOCCAL CONJUGATE VACCINE | BIOLOGICAL E LTD (IN) | 2021-01-20 | — | — | EP | claimed |
| US-20170198004-A1 | NOVEL SEMI-SYNTHETIC MENINGOCOCCAL CONJUGATE VACCINE | BIOLOGICAL E LTD (IN) | 2017-07-13 | — | — | US | claimed |
| EP-3148577-A2 | NOVEL SEMI-SYNTHETIC MENINGOCOCCAL CONJUGATE VACCINE | Biological E Limited (IN) | 2017-04-05 | — | — | EP | claimed |
| WO-2015181834-A2 | NOVEL SEMI-SYNTHETIC MENINGOCOCCAL CONJUGATE VACCINE | BIOLOGICAL E LIMITED (IN) | 2015-12-03 | — | — | WO | claimed |
| US-20110229510-A1 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-09-22 | — | — | US | claimed |
| EP-2315771-A2 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | Sloan Kettering Institute For Cancer Research (US) | 2011-05-04 | — | — | EP | claimed |
| WO-2010006343-A2 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-01-14 | — | — | WO | claimed |
| EP-0996455-B1 | ALPHA-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF | SLOAN KETTERING INST CANCER (US) | 2009-12-16 | — | — | EP | claimed |
| US-20240238328-A1 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | GLYCOLOGIX INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-11975019-B2 | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | GLYCOLOGIX, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-11911411-B2 | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | GLYCOLOGIX, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-115697352-A | Sulfated glycosaminoglycan biomaterials as proteoglycan mimetics | 格莱克罗吉克斯公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-4121064-A1 | SULFATED GLYCOSAMINOGLYCAN BIOMATERIALS AS PROTEOGLYCAN MIMICS | Glycologix, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11420993-B2 | Semi-synthetic meningococcal conjugate vaccine | BIOLOGICAL E LIMITED | 2022-08-23 | — | — | US | disclosed |
| US-20030083235-A1 | Alpha-o-linked glycoconjugates, methods of preparation and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-01 | — | — | US | disclosed |
| EP-1091751-A1 | TRIMERIC ANTIGENIC O-LINKED GLYCOPEPTIDE CONJUGATES, METHODS OF PREPARATION AND USES THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 2001-04-18 | — | — | EP | disclosed |
| EP-0996455-A1 | $g(a)-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999048515-A9 | TRIMERIC ANTIGENIC O-LINKED GLYCOPEPTIDE CONJUGATES, METHODS OF PREPARATION AND USES THEREOF | SLOAN KETTERING INST CANCER (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999048515-A1 | TRIMERIC ANTIGENIC O-LINKED GLYCOPEPTIDE CONJUGATES, METHODS OF PREPARATION AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1998046246-A1 | α-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238328-A1 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | MATR3, CSGALNACT1, CD44 | TSHR 1596/4885LMNA 1160/4885NFKB1 4229/4885 |
| US-11420993-B2 | Semi-synthetic meningococcal conjugate vaccine | STT3B, CD14, DDOST | TSHR 4048/4885LMNA 3410/4885NFKB1 750/4885 |
| US-20170198004-A1 | NOVEL SEMI-SYNTHETIC MENINGOCOCCAL CONJUGATE VACCINE | STT3B, CD14, STT3A | TSHR 3998/4885LMNA 3181/4885NFKB1 853/4885 |
| US-11911411-B2 | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | MATR3, CSGALNACT1, CD44 | TSHR 1596/4885LMNA 1160/4885NFKB1 4229/4885 |
| US-20110229510-A1 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | B3GAT3, MICA, SIGLEC7 | TSHR 2791/4885LMNA 4097/4885NFKB1 3297/4885 |
| US-11975019-B2 | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | CSGALNACT1, MATR3, CD44 | TSHR 1659/4885LMNA 1956/4885NFKB1 4562/4885 |
| US-20030083235-A1 | Alpha-o-linked glycoconjugates, methods of preparation and uses thereof | MUC1, FUT5, FUT6 | TSHR 2210/4885LMNA 3345/4885NFKB1 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.